Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 2 of 2 for:    Intralytix

Assessing the Efficacy of Anti-staphylococcal Phages in the Management of Infected Foot Ulcers in Diabetes (PDFI)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04289948
Recruitment Status : Withdrawn (Funding issues meant that development of the study was halted.)
First Posted : February 28, 2020
Last Update Posted : February 28, 2020
Sponsor:
Collaborators:
Wellcome Trust
BioPhage Theraputics Limited
Nottingham University Hospitals NHS Trust
Information provided by (Responsible Party):
University Hospitals of Derby and Burton NHS Foundation Trust

Brief Summary:
Work Package 1: Observational cohort pilot safety study Work Package 2: Randomised, double-blind, placebo controlled pilot study Work Package 3: Observer-blind pilot RCT

Condition or disease Intervention/treatment Phase
Diabetes Diabetic Foot Diabetic Foot Infection Drug: Phage Phase 1 Phase 2

Detailed Description:

Work Package 1

WP1 is a safety cohort pilot study targeting patients with DFU which are non-infected as determined by the IDSA criteria. 20 participants will be recruited from Diabetic Foot Clinic at the Royal Derby Hospital. Phage gel will be applied to the index ulcer after the first and second sets of measures at baseline, weeks 1, 2 and 3. Samples will be taken at baseline and weekly up to 4 weeks by surface swab and deep tissue sample for determination of bacterial colonisation using both conventional and genotypic (molecular) microbiological methods, prior to any IMP application.

Work Package 2

WP2 is a pilot double blind, placebo-controlled, randomised study targeting patients with mild or moderate infection of DFUs and comparing systemic antibiotic therapy plus phage gel against systemic antibiotics therapy plus placebo gel. A total of 50 participants from two centres (foot clinics at Royal Derby Hospital and City Campus, Nottingham University Hospitals NHS Trust) will be recruited. Phage gel or placebo will be applied to the index ulcer after the first and second sets of measures at baseline, weeks 1, 2 and 3. Samples will be taken at baseline and weekly up to 4 weeks by surface swab and deep tissue sample for determination of bacterial colonisation using both conventional and genotypic (molecular) microbiological methods

Work Package 3

WP3 is an observer-blind RCT targeting patients with mild diabetic foot infection by IDSA criteria and comparing phage gel with systemic antibiotics. A total of 50 participants from two centres (foot clinics at Royal Derby Hospital and City Campus, Nottingham University Hospitals NHS Trust) will be recruited. Those with moderately severe infections will be withheld from this work package because of the clinical and ethical issues associated with withholding antibiotics in those with a moderately severe infection.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 0 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Masking Description: Work Package 1: Observational cohort pilot safety study Work Package 2: Randomised, double-blind, placebo controlled pilot study Work Package 3: Observer-blind pilot RCT
Primary Purpose: Treatment
Official Title: Assessing the Efficacy of Anti-staphylococcal Phages in the Management of Infected Foot Ulcers in Diabetes
Estimated Study Start Date : March 1, 2019
Estimated Primary Completion Date : June 1, 2022
Estimated Study Completion Date : September 1, 2022

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Foot Health

Arm Intervention/treatment
Experimental: Phage Drug: Phage
The studies will be undertaken using a cocktail of at least 2-3 anti-staphylococcal phages produced by Intralytix Inc, Baltimore, Maryland, USA. The phages will be included in a gel designed for application directly to the wound surface and packaged in 5 ml single use tubes.

Placebo Comparator: Placebo Drug: Phage
The studies will be undertaken using a cocktail of at least 2-3 anti-staphylococcal phages produced by Intralytix Inc, Baltimore, Maryland, USA. The phages will be included in a gel designed for application directly to the wound surface and packaged in 5 ml single use tubes.




Primary Outcome Measures :
  1. Work Package 1: To assess the safety of the use of anti-staphylococcal phages therapy on the wound bacterial microbiome of uninfected DFU's. [ Time Frame: 7 months ]
    - Safety : Clinically significant change in safety bloods, vital signs, Full Blood Count (FBC), renal function, C-Reactive protein (CRP), Liver function Tests (LFT)s, Adverse events

  2. Work Package 2 [ Time Frame: 16 months ]
    To compare the effect on the microbiome of empirical systemic antibiotic therapy alone (ESAT) versus ESAT plus phage therapy in ulcers complicated by mild or moderate infection as assessed by IDSA criteria

  3. Work Package 3 [ Time Frame: 16 months ]
    To compare the use of empirical systemic antibiotic therapy versus phage therapy in ulcers complicated by mild infection on the eradication of the infection as assessed by IDSA criteria.


Secondary Outcome Measures :
  1. Work Package 1: Safety of phage gel and overt toxic effect of phage gel. [ Time Frame: 7 months ]

    The following outcomes will be recorded at weekly intervals for 4 weeks from baseline:

    1. Incidence of new infection
    2. Number of days of antibiotic usage
    3. Change in surface microbiome
    4. Adverse events
    5. Change in safety bloods, vital signs, FBC, renal function, CRP, LFTs
    6. Wound status (clinical infection, area, depth, extent of surface slough, pain by VAS, peri ulcer appearance)
    7. Patient well-being using a Visual Analogue Scale, 0-100mm.
    8. Vital signs (Resting pulse and blood pressure (BP))

  2. Work Package 1: • Impact on the bacterial microbiome of anti-staphylococcal phage gel and systemically chosen antibiotics. [ Time Frame: 7 months ]

    The following outcomes will be recorded at weekly intervals for 4 weeks from baseline:

    1. Incidence of new infection
    2. Number of days of antibiotic usage
    3. Change in surface microbiome
    4. Adverse events
    5. Change in safety bloods, vital signs, FBC, renal function, CRP, LFTs
    6. Wound status (clinical infection, area, depth, extent of surface slough, pain by VAS, peri ulcer appearance)
    7. Patient well-being using a Visual Analogue Scale, 0-100mm.
    8. Vital signs (Resting pulse and blood pressure (BP))

  3. Work Package 2: Safety of phage gel and overt toxic effect of phage gel. [ Time Frame: 7 months ]

    The following outcomes will be recorded at weekly intervals for 4 weeks from baseline:

    1. change in surface microbiome
    2. Number of antibiotic-free days
    3. Adverse events
    4. Change in safety bloods, vital signs, FBC, renal function, CRP, LFTs
    5. Wound status (clinical infection, area, depth, extent of surface slough, pain by VAS, peri ulcer appearance)
    6. Patient well-being using a Visual Analogue Scale, 0-100mm.
    7. Eradication of clinical evidence of the infection in the index ulcer at weeks 1, 2 and 3, and time to eradication
    8. Healing of all ulcers and time to healing
    9. Resting pulse and blood pressure (BP)

  4. Work Package 2: Clinical benefit and patient well-being associated with adding phage gel to systemically chosen antibiotics compared to placebo in the management of mild or moderate infection. [ Time Frame: 16 months ]

    The following outcomes will be recorded at weekly intervals for 4 weeks from baseline:

    1. change in surface microbiome
    2. Number of antibiotic-free days
    3. Adverse events
    4. Change in safety bloods, vital signs, FBC, renal function, CRP, LFTs
    5. Wound status (clinical infection, area, depth, extent of surface slough, pain by VAS, peri ulcer appearance)
    6. Patient well-being using a Visual Analogue Scale, 0-100mm.
    7. Eradication of clinical evidence of the infection in the index ulcer at weeks 1, 2 and 3, and time to eradication
    8. Healing of all ulcers and time to healing
    9. Resting pulse and blood pressure (BP)

  5. Work Package 2: Impact on the bacterial microbiome of systemically chosen antibiotics and of anti-staphylococcal phage gel. [ Time Frame: 16 months ]

    The following outcomes will be recorded at weekly intervals for 4 weeks from baseline:

    1. change in surface microbiome
    2. Number of antibiotic-free days
    3. Adverse events
    4. Change in safety bloods, vital signs, FBC, renal function, CRP, LFTs
    5. Wound status (clinical infection, area, depth, extent of surface slough, pain by VAS, peri ulcer appearance)
    6. Patient well-being using a Visual Analogue Scale, 0-100mm.
    7. Eradication of clinical evidence of the infection in the index ulcer at weeks 1, 2 and 3, and time to eradication
    8. Healing of all ulcers and time to healing
    9. Resting pulse and blood pressure (BP)

  6. Work Package 3: Safety of phage gel and overt toxic effect of phage gel. [ Time Frame: 16 months ]

    The following outcomes will be recorded at weekly intervals for 4 weeks from baseline:

    1. Change in surface microbiome
    2. Number of antibiotic-free days
    3. Adverse events
    4. Change in safety bloods, FBC, renal function, CRP, LFTs
    5. Wound status (clinical infection, area, depth, extent of surface slough, pain by VAS, peri ulcer appearance)
    6. Patient well-being using a Visual Analogue Scale, 0-100mm.
    7. Eradication of clinical evidence of the infection in the index ulcer at weeks 1, 2 and 3, and time to eradication
    8. Healing of all ulcers and time to healing
    9. Resting pulse and blood pressure (BP)

  7. Work Package 3: Clinical benefit and patient well-being associated with phage gel therapy compared to systemically chosen antibiotics in the management of mild infection. [ Time Frame: 16 months ]

    The following outcomes will be recorded at weekly intervals for 4 weeks from baseline:

    1. Change in surface microbiome
    2. Number of antibiotic-free days
    3. Adverse events
    4. Change in safety bloods, FBC, renal function, CRP, LFTs
    5. Wound status (clinical infection, area, depth, extent of surface slough, pain by VAS, peri ulcer appearance)
    6. Patient well-being using a Visual Analogue Scale, 0-100mm.
    7. Eradication of clinical evidence of the infection in the index ulcer at weeks 1, 2 and 3, and time to eradication
    8. Healing of all ulcers and time to healing
    9. Resting pulse and blood pressure (BP)

  8. Work Package 3: Impact on the bacterial microbiome of systemically chosen antibiotics and of anti-staphylococcal phage gel. [ Time Frame: 16 months ]

    The following outcomes will be recorded at weekly intervals for 4 weeks from baseline:

    1. Change in surface microbiome
    2. Number of antibiotic-free days
    3. Adverse events
    4. Change in safety bloods, FBC, renal function, CRP, LFTs
    5. Wound status (clinical infection, area, depth, extent of surface slough, pain by VAS, peri ulcer appearance)
    6. Patient well-being using a Visual Analogue Scale, 0-100mm.
    7. Eradication of clinical evidence of the infection in the index ulcer at weeks 1, 2 and 3, and time to eradication
    8. Healing of all ulcers and time to healing
    9. Resting pulse and blood pressure (BP)



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Diabetes Mellitus according to WHO criteria
  2. are aged 18 years or over
  3. Additionally, patients must meet one of the following criteria to participate in the described Work Package:

    • Patients are only eligible for WP1 if they also have one or more DFUs (area 25mm2) below the malleoli without infection according to IDSA criteria that have been present for at least 4 weeks
    • Patients are only eligible for WP2 if they also have one or more DFUs (area 25mm2) below the malleoli with mild or moderate infection according to IDSA criteria that have been present for at least 4 weeks
    • Patients are only eligible for WP3 if they also have one or more DFUs (area 25mm2) below the malleoli with mild infection according to IDSA criteria that have been present for at least 4 weeks

Exclusion Criteria:

We will exclude patients who meet ANY of the following criteria:

  1. with mental incapacity to give informed consent,
  2. who have other major co-morbidities, which in the opinion of the investigator would mean that the patient would not be able to complete the study
  3. with significant peripheral arterial disease (PAD): ABPI (ankle brachial pressure index) <0.7,
  4. Who have osteomyelitis defined by agreed clinical criteria
  5. who are receiving treatment with systemic glucocorticoids or other immunosuppressants,
  6. who have received systemic or topical antibiotics in the preceding 14 days,
  7. who are judged to require parenteral administration of antibiotics,
  8. Who have been previously recruited to an earlier part of the project
  9. who are women of childbearing age who are at risk of conception
  10. History of antibiotic hypersensitivity

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04289948


Locations
Layout table for location information
United Kingdom
University Hospitals Derby and Burton NHS Foundation Trust
Derby, Derbyshire, United Kingdom, DE22 3DT
Sponsors and Collaborators
University Hospitals of Derby and Burton NHS Foundation Trust
Wellcome Trust
BioPhage Theraputics Limited
Nottingham University Hospitals NHS Trust
Layout table for additonal information
Responsible Party: University Hospitals of Derby and Burton NHS Foundation Trust
ClinicalTrials.gov Identifier: NCT04289948    
Other Study ID Numbers: DHRD/2018/080
First Posted: February 28, 2020    Key Record Dates
Last Update Posted: February 28, 2020
Last Verified: February 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by University Hospitals of Derby and Burton NHS Foundation Trust:
Diabetes
Diabetic Foot Disease
Diabetic Foot Ulcer
Additional relevant MeSH terms:
Layout table for MeSH terms
Diabetic Foot
Foot Ulcer
Diabetes Mellitus
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Diabetic Angiopathies
Vascular Diseases
Cardiovascular Diseases
Leg Ulcer
Skin Ulcer
Skin Diseases
Diabetes Complications
Diabetic Neuropathies
Foot Diseases